The article you requested is
Academic Highlights: International Consensus Group on the Evidence-Based Pharmacologic Treatment of Bipolar I and II Depression
J Clin Psychiatry 2008;69:1632-1646
Copyright 2008 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($125) or print + online ($161 individual).
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
In 2004, an International Consensus
Group (ICG) developed and published
recommendations for the treatment
of bipolar I depression based on
available clinical evidence. The ICG
reconvened in October 2007 to reevaluate
clinical trial data published in
the intervening years on the treatment
of bipolar I depression. In addition, the
ICG extended the scope of its discussions
to consider published evidence
for the treatment of bipolar II depression
and also special populations of
patients with bipolar depression.